Although low-dose tPA thrombolysis reduces the risk of hemorrhage, the mortality and disability rates are increased in AIS patients receiving a lower dose of tPA (1–4), presenting an unmet medical need for adjunctive therapies that can enhance the thrombolytic effects of low-dose tPA and maintain its safety advantage. The gene discussed is PLAT; the disease is androgen insensitivity syndrome.